NCT00330018View on ClinicalTrials.gov

Valganciclovir in Prevention of Cytomegalovirus (CMV) Reactivation Following Allogeneic-Stem Cell Transplantation (SCT)

PHASE3CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
Bone Marrow TransplantationCytomegalovirus
Interventions
DRUG

Valganciclovir

Valganciclovir

DRUG

Acyclovir

Acyclovir

Trial Locations (1)

91120

Hadassah Medical Organization,, Jerusalem

All Listed Sponsors
lead

Hadassah Medical Organization

OTHER

NCT00330018 - Valganciclovir in Prevention of Cytomegalovirus (CMV) Reactivation Following Allogeneic-Stem Cell Transplantation (SCT) | Biotech Hunter | Biotech Hunter